2021年7月13日 · Response assessment in neuro-oncology brain metastases (RANO-BM) criteria are recommendations for standardized tumor response and progression assessment in clinical trials involving brain metastases. Published in 2015, these should not be confused with the RANO criteria for high-grade glioma from the same group.

The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary eff ort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases.

RECIST 1.1 mainly referred as assessment criteria in oncology clinical trials, present apparent drawbacks addressed by RANO-BM proposed in 2015. The fundamental of RANO-BM is the separately identified target, non-target, and post-baseline new lesions from intracranial and extracranial lesions.

The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases.

为了提高临床试验中治疗反应评估的可靠性和可比性，并辅助确定更有效的治疗方法，rano工作组于2010年发布了高级别胶质瘤的反应评价标准（rano-hgg），2011年发布了低级别胶质瘤的反应评价标准（rano-lgg）。

An international multidisciplinary group, The Response Assessment in Neuro-Oncology (RANO) Metastatic Working Group has proposed a RANO-Brain Metastases (RANO-BM) Criteria is based on a modification of RECIST 1.1 criteria and uses unidimensional measurements.

2024年2月2日 · rano 2.0标准制定背景. 在胶质瘤不同临床试验中应用rano-hgg、mrano和irano等不同反应评价标准，可能会出现不一致的疗效评估结果。一项针对胶质母细胞瘤的多中心研究发现，不同评价标准在pfs或pfs与os的相关性之间均没有统计学差异。

目前提出的针对bm的疗效评价标准多由胶质瘤评价标准演变而来，其中2015年由国际神经肿瘤疗效评估协作组–bm小组（rano-bm）提出的rano-bm标准结合靶病灶、非靶病灶的影像学大小改变、有无新病灶、糖皮质激素用量及患者临床状态进行全面评估，并对可测量病灶 ...

《用rano - bm标准评价脑转移瘤患者放射外科治疗靶区和非靶区病变的效果》一文，对66例患者分组研究。 阐述了放射外科治疗指征扩大背景下，用RANO - BM标准评估治疗效果的情况。

目前, 对于脑转移疗效的评估体系繁多, 包括recist1.0、recist1.1、macdonald等评估方法。rano工作组在2015年提出了rano-bm疗效评估体系, 对比应用较为广泛的recist体系, 将靶病灶的评价, 从一维的最长径测量改为对结节大小进行垂直交叉两径的评估, 同时在评估时限、激素 ...